Bivigam

The year is drawing to the close, and biotech stocks have had a fairly good run despite the market-wide downturn in October and Novmeber. New molecular moiety (NME) approvals thus far this year totaled 52, already beating the previous year's number of 46. NMEs are active moieties that...

September had several clinical trial results announcements and a few FDA approvals triggering moves in the space. New molecular moiety, or NME, approvals totalled a mere three in September, taking the total NME approvals for 2018 to 37 compared to 46 in 2017. Here are the PDUFA catalysts for...